Bulk RNA-seq of femoral/tibial bone tissues from OVX-induced osteoporosis mice treated with DCNPs, ALN, Mix, OVX controls or healthy controls.

This dataset contains bulk transcriptome sequencing (RNA-seq) data generated from femur/tibia bone tissues collected in a murine ovariectomy (OVX) osteoporosis model to evaluate the therapeutic effects of dynamic covalent nanoparticles (DCNPs). Five experimental groups were profiled:Healthy (sham) (Labelled <i>NC</i> in data file)OP + PBS (PBS)(Labelled <i>OVX </i>in data file)OP + Alendronate (ALN)(Labelled <i>ALN </i>in data file)OP + Mix (EA + ALN + PEI + CaCl2 without 2-FPBA)(Labelled <i>Mix </i>in data file)OP + DCNPs (EA + ALN + PEI + 2-FPBA + CaCl2) (Labelled <i>NPs </i>in data file)<br>Female C57BL/6J mice were used. The goal is to characterize DCNP-mediated transcriptional reprogramming in bone, including activation of JAK2–STAT3 signaling and suppression of inflammatory lipid metabolism pathways identified in the companion manuscript.<br>Provider<br>Sequencing was performed by Lianchuan Company (commercial service provider).Assay and platformAssay type: Bulk RNA-seq (poly(A)+ selection; stranded library)Platform: Illumina NovaSeq 6000Read configuration: paired-end 2 × 150 bpSamplesSpecies/strain/sex: Mus musculus, C57BL/6J, femaleModel: Ovariectomy (OVX) osteoporosis model; sham for HealthyTissue: Femur and tibia (bone)Groups and size: 5 groups × n = 3 biological replicates per group = 15 libraries totalAge at surgery: 8 weeks; therapy period: 8 weeksTreatments: Healthy; PBS; ALN (1.4 mg/kg/week, IV); Mix (same ALN dose); DCNPs (same ALN dose embedded in DCNPs), twice weekly IV injectionsHarvest: endpoint at week 16Ethics: Approved by the Laboratory Animal Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (No. WYYY-AEC-2025-008)Data content and organization